Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
- PMID: 1354166
- DOI: 10.1016/0014-4886(92)90125-a
Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
Abstract
A group of four drug naive Macaca fascicularis were rendered parkinsonian with the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine and then treated chronically with (+)-PHNO, a potent D2 agonist. After several days, dyskinesia appeared in all animals. At this point, the daily dose of (+)-PHNO was replaced by a dose of the D1 agonist CY 208-243. The substitution by CY 208-243 reproduced the same dyskinesia observed with (+)-PHNO. The administration of the DA synthesis inhibitor AMPT (alpha-methyl-p-tyrosine methyl ester) blocked the dyskinetic and antiparkinsonian effect of (+)-PHNO, and those effects were reestablished by the addition of a subthreshold dose of CY 208-243. Our results show that a selective D2 agonist is capable of inducing dyskinesia and suggest some kind of cooperation between D1 and D2 receptors in the antiparkinsonian and dyskinetic effect produced by (+)-PHNO.
Similar articles
-
Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.Eur J Pharmacol. 1994 Mar 3;253(3):215-24. doi: 10.1016/0014-2999(94)90194-5. Eur J Pharmacol. 1994. PMID: 7911084
-
Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.Neurosci Lett. 1993 Nov 26;163(1):31-5. doi: 10.1016/0304-3940(93)90222-7. Neurosci Lett. 1993. PMID: 7905197
-
The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.Adv Neurol. 1993;60:119-22. Adv Neurol. 1993. PMID: 8093574 No abstract available.
-
Neurotoxin-related research: from the laboratory to the clinic.Ann N Y Acad Sci. 1992 May 11;648:207-18. doi: 10.1111/j.1749-6632.1992.tb24540.x. Ann N Y Acad Sci. 1992. PMID: 1353328 Review. No abstract available.
-
MPTP induced parkinsonian syndrome: long term follow-up and neurophysiological study.Ital J Neurol Sci. 1990 Oct;11(5):445-58. doi: 10.1007/BF02336564. Ital J Neurol Sci. 1990. PMID: 2272779 Review. No abstract available.
Cited by
-
The Dynamics of Dopamine D2 Receptor-Expressing Striatal Neurons and the Downstream Circuit Underlying L-Dopa-Induced Dyskinesia in Rats.Neurosci Bull. 2023 Sep;39(9):1411-1425. doi: 10.1007/s12264-023-01054-5. Epub 2023 Apr 6. Neurosci Bull. 2023. PMID: 37022638 Free PMC article.
-
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.Behav Brain Res. 2014 Aug 15;270:75-85. doi: 10.1016/j.bbr.2014.05.009. Epub 2014 May 13. Behav Brain Res. 2014. PMID: 24837745 Free PMC article.
-
Non-human primate models of PD to test novel therapies.J Neural Transm (Vienna). 2018 Mar;125(3):291-324. doi: 10.1007/s00702-017-1722-y. Epub 2017 Apr 8. J Neural Transm (Vienna). 2018. PMID: 28391443 Review.
-
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Clin Interv Aging. 2010 Sep 7;5:229-38. doi: 10.2147/cia.s6456. Clin Interv Aging. 2010. PMID: 20852670 Free PMC article. Review.
-
Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.J Clin Invest. 2017 Feb 1;127(2):720-734. doi: 10.1172/JCI90132. Epub 2017 Jan 23. J Clin Invest. 2017. PMID: 28112685 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources